← Leaderboards
Matthew Ku
O-Ray Pharma, Inc.
$1,025,035
Attributed
$2,050,070
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $886.6K · FY2020–23$1M$750K$500K$250K$0
'20
'21
'22
'23
Funding mix
By agency
NIH$2,050,070 · 2
By mechanism
R44$2,050,070 · 2
Top collaborators
- William H Slattery3 shared
Most similar at O-Ray Pharma, Inc.
Same institution · by research overlap
- William H Slattery$3,101,465
- Erik Pierstorff$2,278,637
Others in their field
Other Emerging Leaders on “Otitis Media”
- Elaine Larkie Horn-Ranney · Tympanogen, Llc$4,715,143
- Peter Luke Santa Maria · Stanford University$3,374,661
- Norberto Gonzalez-Juarbe · J. Craig Venter Institute, Inc.$3,213,772
- Gabrielle Ryan Merchant · Father Flanagan'S Boys' Home$2,528,744
- Nadeem Khan · University Of Florida$2,271,953
- Jarrod Mousa · University Of Georgia$2,198,442
Research focus
Otitis MediaPre-ClinicalFeedbackMeetingsOtologyPhase 1 StudyDexamethasoneEnvironmentHearing ImpairmentImplantationDesignAnti-Inflammatory AgentsPharmaceutical PreparationsCiprofloxacinAffectComplicationDrug Delivery SystemsClinical ResearchFormulationClinical TrialsHydrogelsImplantChemistryPreparation
Grant awards (3)
IND-enabling Preclinical Development of Sustained Release Inner Ear Delivery of Corticosteroid$879,062
R44 · FY2023 · AI · contact PI
IND-enabling Preclinical Development of Sustained Release Inner Ear Delivery of Corticosteroid$886,552
R44 · FY2022 · AI · contact PI
Prevention of Children's Tympanostomy Tube Otorrhea$284,456
R44 · FY2020 · DC · contact PI